Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of iTeos Therapeutics's Belrestotug?
Belrestotug is a monoclonal antibody commercialized by iTeos Therapeutics, with a leading Phase II program in Solid Tumor. According to...
Risk adjusted net present value: What is the current valuation of GSK's Belrestotug?
Belrestotug is a monoclonal antibody commercialized by GSK, with a leading Phase II program in Solid Tumor. According to Globaldata,...
Belrestotug by ITeos Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
Belrestotug is under clinical development by ITeos Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Belrestotug by GSK for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Belrestotug is under clinical development by GSK and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma....
Risk adjusted net present value: What is the current valuation of iTeos Therapeutics's Belrestotug?
Belrestotug is a monoclonal antibody commercialized by iTeos Therapeutics, with a leading Phase II program in Squamous Non-Small Cell Lung...